Celldex Therapeutics Inc (CLDX) said its experimental vaccine for the the most common type of brain cancer met the main goal of extending survival time for patients without a progression of the disease in a mid-stage trial.
The company's injectable CDX-110 is designed to treat glioblastoma, the most common and aggressive type of brain cancer. It extended survival in a trial of 65 brain cancer patients.
The company plans a larger, clinical trial in the second half of next year. As a trader or as a long term position maker, one should focus on acquiring in the $4.50 to $5 range during pullbacks and then holding steady for 2-3 years. Initiate small positions and stay put. Also, be sure to set your mental loss tolerance well before you put money in.
No comments:
Post a Comment
Your comments and opinions here!